November 1, 1997Journal of Cardiovascular Pharmacology

Pharmacologic Profiles of KRH-594, a Novel Nonpeptide Angiotensin II-Receptor Antagonist

View Full Paper

Ask AI

Bookmark

Structured PICO

Population

Preclinical models including rat liver membranes, bovine cerebellar membranes, isolated rabbit aorta, normotensive rats, and spontaneously hypertensive rats (SHRs)

Intervention

KRH-594 (in vitro and in vivo, including 1 mg/kg p.o. in SHRs)

Comparator

Losartan (10 mg/kg p.o.) in SHRs

Outcome

AT1 receptor binding affinity and blood pressure reductionsurrogate

KRH-594 is a novel, highly specific AT1 receptor antagonist with potent blood pressure-lowering effects in preclinical models.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports preclinical development of KRH-594; leaves open clinical translation and human efficacy trials.

Cite This Study

Tamura et al. (1997) studied this question.

synapsesocial.com/papers/6a892f9646f665d098761227 https://doi.org/10.1097/00005344-199711000-00011

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Pharmacologic Profiles of KRH-594, a Novel Nonpeptide Angiotensin II-Receptor Antagonist

Structured PICO

Discussion

Implication

Cite This Study

Topics

Pharmacologic Profiles of KRH-594, a Novel Nonpeptide Angiotensin II-Receptor Antagonist

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider